GH-21
- Generic Name
- GH-21
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT06435455
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumor With Oncogenic Driver MutationsPatients With Advanced Solid Tumor
- Interventions
- Drug: PD-1Drug: ALK inhibitorDrug: BRAF InhibitoDrug: EGFR Monoclonal antibodyDrug: MEK Inhibitor
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06322095
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Genhouse Bio Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT06306456
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung CancerCancer of PancreasCancer of ColonColorectal CancerPancreatic CancerSolid TumorCancer
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- HUYABIO International, LLC.
- Target Recruit Count
- 42
- Registration Number
- NCT05163028
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA Hematology/Oncology, Santa Monica, California, United States
🇺🇸BRCR Medical Center, Plantation, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath